Targeting of two aspects of metabolism in breast cancer treatment

References

• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476:346-50; PMID:21760589; http://dx.doi.org/10.1038/nature10350
   PubMed Web of Science ®Google Scholar
• Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, Harris IS, Holmes R, Wakeham A, Haight J, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488:656-9; PMID:22763442; http://dx.doi.org/10.1038/nature11323
   PubMed Web of Science ®Google Scholar
• Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011; 25:1041-51; PMID:21576264; http://dx.doi.org/10.1101/gad.1987211
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11:37-51; PMID:17222789; http://dx.doi.org/10.1016/j.ccr.2006.10.020
   PubMed Web of Science ®Google Scholar
• McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008; 283:22700-8; PMID:18541534; http://dx.doi.org/10.1074/jbc.M801765200
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Greene YJ. Dichloroacetate. Diabetes Care 1992; 15:785-91; PMID:1600837; http://dx.doi.org/10.2337/diacare.15.6.785
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983; 309:390-6; PMID:6877297; http://dx.doi.org/10.1056/NEJM198308183090702
   PubMed Web of Science ®Google Scholar
• Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol 2013; 3:38; PMID:23471124; http://dx.doi.org/10.3389/fonc.2013.00038
   PubMedGoogle Scholar
• Garber K. Oncology's energetic pipeline. Nat Biotechnol 2010; 28:888-91; PMID:20829819; http://dx.doi.org/10.1038/nbt0910-888
   PubMed Web of Science ®Google Scholar
• Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2013; 32:452-64; PMID:24297161; http://link.springer.com/article/10.1007%2Fs10637-013-0047-4
   PubMed Web of Science ®Google Scholar
• Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2014; 140:443-52; PMID:24442098; http://dx.doi.org/10.1007/s00432-014-1583-9
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Translational Med 2010; 2:31ra4; http://dx.doi.org/10.1126/scitranslmed.3000677
   Web of Science ®Google Scholar
• Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2010; 120:253-60; PMID:19543830; http://dx.doi.org/10.1007/s10549-009-0435-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One 2009; 4:e7033; PMID:19753307; http://dx.doi.org/10.1371/journal.pone.0007033
   PubMed Web of Science ®Google Scholar
• Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010; 31:567-76; PMID:20080835; http://dx.doi.org/10.1093/carcin/bgq012
   PubMed Web of Science ®Google Scholar
• Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, Parker JM, McMurtry MS, Michelakis ED. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene 2013; 32:1638-50; PMID:22614004; http://dx.doi.org/10.1038/onc.2012.198
   PubMed Web of Science ®Google Scholar
• Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J, Lanvers-Kaminsky C. Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 2010; 67:647-55; PMID:20502900; http://dx.doi.org/10.1007/s00280-010-1361-6
   PubMed Web of Science ®Google Scholar
• Sun RC, Board PG, Blackburn AC. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer 2011; 10:142; PMID:22093145; http://dx.doi.org/10.1186/1476-4598-10-142
   PubMed Web of Science ®Google Scholar
• Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. Chem Commun (Camb) 2012; 48:10730-2; PMID:23012698; http://dx.doi.org/10.1039/c2cc34297a
   PubMed Web of Science ®Google Scholar
• Xie J, Wang BS, Yu DH, Lu Q, Ma J, Qi H, Fang C, Chen HZ. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J Oncol 2011; 38:409-17; PMID:21132264
   PubMed Web of Science ®Google Scholar
• Xue X, You S, Zhang Q, Wu Y, Zou GZ, Wang PC, Zhao YL, Xu Y, Jia L, Zhang X, et al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Mol Pharm 2012; 9:634-44; PMID:22289032; http://dx.doi.org/10.1021/mp200571k
   PubMed Web of Science ®Google Scholar
• Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 2010; 127:2510-9; PMID:20533281; http://dx.doi.org/10.1002/ijc.25499
   PubMed Web of Science ®Google Scholar
• Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15:476-84; PMID:19147752; http://dx.doi.org/10.1158/1078-0432.CCR-08-0930
   PubMed Web of Science ®Google Scholar
• Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, Hogg PJ. Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem 2009; 52:6209-16; PMID:19788237; http://dx.doi.org/10.1021/jm9008339
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281:1322-6; PMID:9735050; http://dx.doi.org/10.1126/science.281.5381.1322
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516; PMID:17562483; http://dx.doi.org/10.1080/01926230701320337
   PubMed Web of Science ®Google Scholar
• Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2:67-71; PMID:11413468; http://dx.doi.org/10.1038/35048073
   PubMed Web of Science ®Google Scholar
• Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B, Kroemer G. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996; 384:53-7; PMID:8797802; http://dx.doi.org/10.1016/0014-5793(96)00280-3
   PubMed Web of Science ®Google Scholar
• Park D, Chiu J, Perrone GG, Dilda PJ, Hogg PJ. The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Int 2012; 12:11; PMID:22448968; http://dx.doi.org/10.1186/1475-2867-12-11
   PubMed Web of Science ®Google Scholar
• Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003; 3:497-509; PMID:12781367; http://dx.doi.org/10.1016/S1535-6108(03)00109-0
   PubMed Web of Science ®Google Scholar
• Gang BP, Rooke M, Mishra S, Dahlstrom JE, Blackburn AC. Sensitivity to Dichloroacetate is Determined by PDK Expression. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; Apr 6-10; Washington, DC. Cancer Research 2013; 73(8): Supplement 1; http://dx.doi.org/10.1158/1538-7445.AM2013-5421
   Google Scholar
• Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009; 46:821-31; PMID:19265700; http://dx.doi.org/10.1016/j.yjmcc.2009.02.021
   PubMed Web of Science ®Google Scholar
• Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 2008; 68:1223-31; PMID:18465755; http://dx.doi.org/10.1002/pros.20788
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989; PMID:18766181; http://dx.doi.org/10.1038/sj.bjc.6604554
   PubMed Web of Science ®Google Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14:198-206; PMID:15254862; http://dx.doi.org/10.1016/j.semradonc.2004.04.008
   PubMed Web of Science ®Google Scholar
• Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-3; PMID:8640781
   PubMed Web of Science ®Google Scholar
• Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20:680-7; PMID:11821448; http://dx.doi.org/10.1200/JCO.20.3.680
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 2004; 43:396-403; PMID:15303502; http://dx.doi.org/10.1080/02841860410026189
   PubMed Web of Science ®Google Scholar
• Shen H, Decollogne S, Dilda PJ, Chung S, Luk P, Hogg PJ, McDonald KL. PENAO, a Novel Mitochondria-Targeted Agent, Synergizes with Dichloroacetate to Target Aberrant Glucose Metabolism in Glioblastoma. 4th Quadrennial Meeting of the World Federation of Neuro-Oncology; November 21st-24th; San Francisco, CA. Neuro-Oncology 2013; (S3):58; WOS:000327456200243.
   Google Scholar
• Ayyanathan K, Kesaraju S, Dawson-Scully K, Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One 2012; 7:e39949; PMID:22866174; http://dx.doi.org/10.1371/journal.pone.0039949
   PubMed Web of Science ®Google Scholar
• Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, et al. Inactivation of the HIF-1alphaPDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012; 72:5035-47; PMID:22865452; http://dx.doi.org/10.1158/0008-5472.CAN-12-0979
   PubMed Web of Science ®Google Scholar
• Lim CE, Matthaei KI, Blackburn AC, Davis RP, Dahlstrom JE, Koina ME, Anders MW, Board PG. Mice deficient in glutathione transferase zetamaleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol 2004; 165:679-93; PMID:15277241; http://dx.doi.org/10.1016/S0002-9440(10)63332-9
   PubMed Web of Science ®Google Scholar